Interim report
Page 1
Half - Year Report Q2 2026 Innovative immunotherapies for a healthier world Nasdaq First North : EXPRS2 Expres2ion Biotech Holding AB Company reg . no . 559033-3729 expres2ion BIOTECH
Loading workspace
Half - Year Report Q2 2026 Innovative immunotherapies for a healthier world Nasdaq First North : EXPRS2 Expres2ion Biotech Holding AB Company reg . no . 559033-3729 expres2ion BIOTECH
Your watchlist and earnings event details are available after you sign in.